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Abstract In this report, we have investigated whether altera-
tions of the morphological and functional aspects of the
biosecretory membrane system are associated with the metastatic
potential of tumor cells. To this end, we have analyzed the
morphology of the Golgi complex, the cytoskeleton organization
and membrane trafficking steps of the secretory pathway in two
human melanoma A375 cell line variants with low (A375-P) and
high metastatic (A375-MM) potential. Immunofluorescence
analysis showed that in A375-P cells, the Golgi complex showed
a collapsed morphology. Conversely, in A375-MM cells, the
Golgi complex presented a reticular and extended morphology.
At the ultrastructural level, the Golgi complex of A375-P cells
was fragmented and cisternae were swollen. When the cyto-
skeleton was analyzed, the microtubular network appeared
normal in both cell variants, whereas actin stress fibers were
largely absent in A375-P, but not in A375-MM cells. In addition,
the F-actin content in A375-P cells was significantly lower than
in A375-MM cells. These morphological differences in A375-P
cells were accompanied by acceleration and an increase in the
endoplasmic reticulum to Golgi and the trans-Golgi network to
cell surface membrane transport, respectively. Our results
indicate that in human A375 melanoma cells, metastatic
potential correlates with a well-structured morphofunctional
organization of the Golgi complex and actin cytoskeleton.
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1. Introduction
All proteins destined for secretion, as well as those targeted
to specialized organelles, undergo a series of conformational
(secondary and tertiary structure acquisition) and chemical
(glycosylation, sulfation, phosphorylation, etc.) post-transla-
tional modi¢cations within the endoplasmic reticulum (ER)
and the Golgi complex (GC). Furthermore, the GC itself is
the most important protein sorting station in the cell [1]. In
particular, it is at the trans-Golgi network (TGN), the most
distal region of the GC, where proteins and lipids are sorted
to their ¢nal destinations [2]. Thus, the GC plays a pivotal
role in the cell physiology and has a highly conserved mor-
phology in mammalian cells [3]. Some human diseases can be
caused by defects in the intracellular protein and lipid tra⁄c
both in the secretory and endocytic pathways [4] and altera-
tions in the GC can cause human disease or contribute to
pathogenesis [5]. For example, morphological GC alterations
such as fragmentation or hypertrophy have been described in
certain viral diseases [6^8], in amyotrophic lateral sclerosis [9],
in Alzheimer’s disease [10,11] and in familial high density lip-
oprotein de¢ciency or Tangier disease [12]. Functional GC
alterations have also been involved in cystic ¢brosis [13], au-
tosomal dominant polycystic kidney disease [14,15], type C
Niemann-Pick disease [16], congenital sucrase-isomaltase dis-
ease [17] and in Lowe syndrome [18].
Fundamental features in human neoplasia are cell transfor-
mation and the acquisition of invasive and metastatic poten-
tial, one of the major causes of failure of many therapeutical
approaches on the primary tumor. Alterations in the GC
structure, abnormal distribution of Golgi markers in the ER
and alterations in the intracellular tra⁄c of proteins have been
reported in cancer cells [19^22]. These disorders could con-
tribute to the appearance of the aberrant glycosylation asso-
ciated with cell transformation and metastasis [23^25]. Con-
sequently, the study of the GC in tumor cells appears relevant
since the majority of glycosyltransferases and glycohydrolases
are compartmentalized in the GC [26].
To study the alterations of the biosecretory pathway asso-
ciated with metastatic potential, we have used the human
melanoma A375 cell line model. This cell model has been
widely utilized in numerous invasion and metastasis studies
([27^30], amongst others). We report that the GC of A375-P
cells is collapsed and fragmented, whereas in A375-MM cells,
the GC displays a reticular and extended network. Further-
more, in A375-P cells, the morphological alterations in the
GC are correlated with the disruption of the actin cytoskele-
ton and lead to an acceleration and an increased rate of the
ER to Golgi and TG/TGN to cell surface transport routes,
respectively. The signi¢cance of these results in relation with
the metastatic potential is discussed.
2. Materials and methods
2.1. Cell culture
Human melanoma cell lines A375-P, A375-MM (characterized by
low and high metastatic potential, respectively) were cultured in Dul-
becco’s modi¢ed Eagle’s medium (DMEM) (Gibco BRL, Oxbridge,
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UK) with Ham-F12 (1:1) supplemented with 10% fetal calf serum
(FCS). The cells were grown at 37‡C in a humidi¢ed atmosphere of
5% CO2. Importantly, A375-P and A375-MM cell variants are peri-
odically tested for their metastatic potential in vivo, according to their
ability to form lung tumor nodules after i.v. injection [31].
2.2. Immuno£uorescence
Cells were grown on coverslips to 70^90% con£uence, washed in
PBS (0.01 M phosphate bu¡er, 0.15 M NaCl, pH 7.2) and ¢xed either
by immersion in cold methanol (320‡C) for 2 min or in freshly pre-
pared paraformaldehyde (4% in PBS) at room temperature for 15 min.
Cells were then washed in PBS and in the case of paraformaldehyde
¢xation, auto£uorescence was quenched by incubation with 50 mM
NH4Cl in PBS for 30 min. Next, cells were permeabilized for 15 min
with PBS containing 0.1% saponin and 1% BSA and processed for
single or double staining immuno£uorescence using the following
primary antibodies: rabbit anti-mannosidase II (from Dr Velasco,
University of Sevilla, Spain), rabbit anti-L-COP (from Dr T. Kreis,
University of Geneva, Switzerland), TRITC-phalloidin (from a 0.2
mg/ml stock solution: Sigma, St. Louis, MO, USA). Polyclonal or
monoclonal antibodies were visualized with TRITC or FITC anti-
rabbit or anti-mouse IgG (FabP)2 fragments (Boehringer Mannheim,
Mannheim, Germany). Samples were viewed under an Olympus
BU60 £uorescence microscope.
2.3. Transmission electron microscopy
Cells were washed twice in 0.1 M Na-cacodylate bu¡er (pH 7.4)
and ¢xed with 2.5% glutaraldehyde in the same bu¡er for 30 min at
room temperature. Cells were then washed three times for 5 min each
with 0.1 M cacodylate bu¡er and post-¢xed with 1% (v/v) OsO4/1.5%
(w/v) K4Fe(CN)6 in 0.1 M cacodylate bu¡er for 1 h at 4‡C. Cells were
scraped from the dishes and centrifuged. Cell pellets were rinsed in
distilled water and stained en bloc with 1% aqueous uranyl acetate for
1 h, followed by dehydration through graded ethanol solutions and
embedded in Epon 812. Ultrathin sections were stained with lead
citrate for 2 min and observed with a Philips 301 electron microscope.
2.4. Fluorescent phalloidin binding assay (F-actin content)
Cell cultures were ¢xed in 4% paraformaldehyde in PBS for 15 min
and permeabilized with 0.1% Triton X-100 in PBS for 5 min. After
three washes in PBS, cells were incubated with TRITC-phalloidin
(from a 0.2 mg/ml stock solution) in PBS for 15 min, washed three
times in PBS and extracted with methanol for 25 min at room temper-
ature. The £uorescence intensity of the supernatants was quanti¢ed in
a Kontron Instruments £uorimeter (SFM25) at 554 nm and 573 nm
excitation and emission wavelengths, respectively.
2.5. Virus infection and vesicular stomatitis virus (VSV)-G transport
assay by the Endo H resistance form acquisition
Cell monolayers were infected with the ts045 temperature-sensitive
mutant VSV in DMEM without serum at 32‡C. At 4 h post-infection
in DMEM containing 10% FCS, cells were incubated for 15 min in
methionine-free DMEM at 40‡C and pulse-labelled in suspension for
10 min with 100 WCi/ml Pro-Mix[35S] (Amersham, Buckinghamshire,
UK) at 40‡C. Cells were washed with ice-cold PBS and chased at 32‡C
in methionine-containing media for the indicated times. Cells were
then washed twice with ice-cold PBS and lysed for 15 min on ice
with Triton X-100 lysis bu¡er (1% Triton X-100, 50 mM Tris-HCl,
pH 8.0, 62.5 mM EDTA) at 4‡C for 30 min and centrifuged at 14 000
rpm for 15 min. 200 Wl of detergent solution (62.5 mM EDTA, 50 mM
Tris-HCl, pH 8.0, 0.4% DOC, 1% NP40), 8.5 Wl of 10% SDS and 2 Wl
of mouse monoclonal P5D4 anti-VSV-G protein antibody (Sigma, St.
Louis, MO, USA) were added to supernatants overnight at 4‡C. Next,
rabbit anti-mouse IgG (DAKO, Denmark) was added for 1 h at room
temperature and 20 Wl of protein A/G agarose (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) was added for 45 min at room temper-
ature. The pellet was washed three times in RIPA bu¡er (10 mM Tris-
HCl pH 7.4, 0.1% SDS, 1% DOC, 1% NP40, 0.15 M NaCl), three
times in TENEN high salt bu¡er (10 mM Tris-HCl, pH 7.2, 0.5 M
NaCl, 1 mM EDTA, 0.5% NP40, 0.1% SDS) and twice in PBS. Pro-
tein A/G agarose beads were resuspended in 10 Wl BH1 bu¡er (0.1 M
sodium acetate, pH 5.5, 1% SDS, 0.1% Triton X-100) and proteins
were eluted from the beads by heating at 95‡C for 5 min. The super-
natant was recovered by centrifugation and 30 Wl BH2 bu¡er (0.1 M
sodium acetate, pH 5.5, 1 mM PMSF, 5 Wg/ml aprotinin, 1 mM
benzamidin) was added. To assay the Endo H-sensitivity, 0.25 mU
Endo H (Boehringer Mannheim, Mannheim, Germany) was added
and the reaction was performed overnight at 37‡C. Samples were
analyzed under reducing conditions in 7.5% SDS-PAGE and gels
were £uorographed. Band quantitation was performed with the
Fig. 1. Immuno£uorescence microscopy showing the morphology of the GC stained for the Golgi resident protein mannosidase II (ManII) (A,
B) and the Golgi-associated protein L-COP (C, D) in A375-P (A, C) and A375-MM (B, D) cells. In A375-P cells, the GC is collapsed in a jux-
ta- or supranuclear positioning, whereas in A375-MM cells, the GC shows a reticular and extended morphology with perinuclear localization.
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Phoretix image analysis software (Phoretix International, Newcastle,
UK).
2.6. Constitutive release of glycosaminoglycans (GAGs)
Cells cultured at con£uence in 12 well plates were washed, incu-
bated with xyloside for 15 min, labelled with [35S]sulfate and treated
for release as described previously [32]. Release media were collected
and centrifuged (14 000Ug, 5 min) and the supernatants recovered.
Cell monolayers were extracted with 0.5 ml of 0.1 M NaOH for at
least 30 min at 37‡C. [35S]sulfate-labelled GAGs were quanti¢ed by a
precipitation assay. Brie£y, cell supernatants and extracts (0.5 ml)
were precipitated overnight at room temperature by the addition of
chondroitin sulfate (0.5 mg/ml ¢nal concentration) and cetylpyridi-
nium chloride (1% ¢nal concentration). Precipitates were recovered
by centrifugation (4000Ug for 10 min) and washed twice with 1%
cetylpyridinium chloride in NaCl (20 mM). Finally, pellets were dis-
solved in NaCl (2 M) at 37‡C and the radioactivity was measured in a
scintillation counter.
3. Results
The morphology of the GC was studied at the immuno-
£uorescence level with antibodies against the cis/middle Golgi
marker mannosidase II (Figs. 1A, B and 3B, D). In A375-P
cells, the GC appeared with a collapsed morphology in a
juxta- or supranuclear position (Figs. 1A and 3B) while in
A375-MM cells, the GC showed a reticular and extended
morphology and was perinuclearly located (Fig. 1B and
3D). Similar results were obtained when both cell variants
were immunostained for the Golgi-associated protein L-COP
(Fig. 1C, D) and for other Golgi resident protein markers
such as MG-160 or galactosyltransferase (not shown). When
the Golgi ultrastructure was studied at the EM level in A375-
P cells, the GC was fragmented with shortened and swollen
cisternae (Fig. 2A). On the contrary, A375-MM cells featured
a GC with long and £attened cisternae (Fig. 2B).
It is well known that the GC morphology and subcellular
positioning is determined by the cytoskeleton organization
[33]. We thus studied the microtubule and actin cytoskeletons
in both cell variants. Immuno£uorescence staining of micro-
tubules with anti-L-tubulin antibodies showed that the micro-
tubular cytoskeleton was not altered either in A375-P and
A375-MM cells (not shown). On the other hand, it has re-
cently been shown that the GC morphology is also maintained
by actin micro¢laments [22,34]. Therefore, A375 cell variants
were double-stained for GC with anti-mannosidase II anti-
bodies and for polymerized actin with phalloidin (Fig. 3).
A375-P cells presented fewer actin stress ¢bers than A375-
MM cells (Fig. 3A and C, respectively). This morphological
di¡erence in the arrangement of actin was con¢rmed by the
F-actin quantitation. Indeed, in A375-P cells, the F-actin
content was signi¢cantly lower than in A375-MM cells (Fig.
3E).
Fig. 2. Transmission electron microscopy of the GC in A375-P and A375-MM cells. In A375-P cells (A), the GC shows a disorganized struc-
ture with cisternal fragmentation and swelling. Conversely, the GC of the A375-MM cells (B) presents the common stacked morphology of £at-
tened cisternae. GC, Golgi complex; N, nucleus.
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To assess the physiological signi¢cance of the di¡erences in
GC morphology between the A375 cell variants, we investi-
gated whether there were alterations in membrane transport
along the secretory pathway. In particular, we have analyzed
biochemically the ER to GC and the TG/TGN to cell surface
transport steps. The ER to GC transport was assayed by
studying di¡erences in the processing of newly synthesized
VSV-G glycoprotein to the Endo H resistant form. In A375-
P cells, a more rapid acquisition of VSV-G Endo H resistance
was observed, relative to A375-MM cells (Fig. 4). Subse-
quently, we have studied the constitutive TG/TGN to cell
surface membrane transport step. Thus, [35S]sulfate-labelled
GAGs were used as markers [32,35] because GAGs are solu-
ble and are sulfated at the most distal Golgi compartments
[36,37]. As can be observed in Fig. 5, the time course of con-
stitutive GAGs release indicates that their transport is signi¢-
cantly higher in A375-P versus A375-MM cells.
4. Discussion
We have investigated the structural and functional altera-
tions of the secretory pathway associated with the metastatic
potential in a well-established human metastatic melanoma
model, the A375 cell line. To our knowledge, this is the ¢rst
study that attempts to associate alterations of the constitutive
secretory pathway with metastatic potential. Initially, we fo-
cused on the GC since this organelle is the central processing
and sorting station of the secretory pathway. At the immuno-
£uorescence level, the GC of A375-MM cells showed a retic-
ular and extended morphological network with a perinuclear
Fig. 3. Fluorescence double staining of F-actin (A, C) and the GC (B, D) and quantitative analysis of the F-actin content (E) in A375-P
(A, B) and A375-MM (C, D) cells. Phalloidin staining of polymerized actin clearly shows that A375-P cells contain less actin stress ¢bers than
A375-MM cells. This visual observation is quantitatively con¢rmed when the F-actin content is measured (E). Note the di¡erent GC morphol-
ogy in both cell variants already shown in Fig. 1.
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location, but in A375-P cells, the GC appeared collapsed in a
supra- or juxtanuclear area. Ultrastructurally, in A375-P cells,
the Golgi stacks were fragmented and presented swelling of
cisternae. These morphological alterations resemble those ob-
served in NRK cells when treated with actin-disrupting agents
such as cytochalasin D [24] or conditionally transformed by
oncogenic N-ras [22]. We thus analyzed the state of the actin
cytoskeleton in both A375 cell line variants. In A375-P cells,
actin stress ¢bers were poorly organized relative to the abun-
dant and well-organized ones of the A375-MM cells. These
morphological di¡erences were con¢rmed by the biochemical
measurement of the F-actin content. Thus, our results indicate
that the lower metastatic potential of A375-P cells is associ-
ated with a collapsed GC morphology, a low F-actin content
and a reduced presence of actin stress ¢bers. Similar results
were also observed in another human melanoma cell line with
a low metastatic potential (A2058: I. Ayala, A. Fabra and G.
Egea, unpublished observations). Our results are in accord-
ance with those indicating that the ability of tumor cells to
invade and metastasize is correlated to increased levels of
polymerized actin, which itself depends on Rho-mediated sig-
nal transduction pathways [38^40]. Interestingly, drugs that
alter actin polymerization have been shown to reduce tumor
growth and the metastatic potential [38,41^43]. Previously, we
have demonstrated that the GC morphology is associated
with actin micro¢laments [22,34]. The current study indicates
that, in the human melanoma A375 cell line, metastatic po-
tential is correlated with a well-structured GC and actin cy-
toskeleton. On the contrary, low metastatic potential is char-
acterized by actin disassembly, a low F-actin content and,
consequently, the morphological collapse of the GC. Interest-
ingly, in undi¡erentiated human colon carcinoma HT29 cells,
it has been reported that the GC was exclusively associated
with actin micro¢laments and Golgi cisternae were also swol-
len [44]. Furthermore, the disappearance or absence of actin
stress ¢bers and decreasing F-actin content levels have been
reported to be correlated with cell transformation [45,46].
Finally, we have also observed that A375-P cells show a
shorter doubling time than A375-MM cells (I. Ayala, G.
Egea and A. Fabra, unpublished results). It is tempting to
speculate that the morphofunctional alterations of the GC
are a consequence of this higher proliferative activity. Thus,
cells with a higher proliferative activity would not require a
well-structured GC. This could also be a consequence of
having a poorer actin cytoskeleton organization. Further-
more, as a consequence of the higher proliferation rate,
A375-P cells could feature higher and/or accelerated ER to
Golgi and TGN to cell surface transport rates because of
the increased requirement for membrane components. On
the contrary, in A375-MM cells, the proliferative rate is not
so high and thus, there is a better organized actin cytoskeleton
and structured GC.
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